EETimes reports today: “With our disruptive pipeline in novel IVD [in-vitro diagnostic] products, we aim to make a major contribution to resolving some of the most intractable problems in health care globally, including antimicrobial resistance [and] the early detection of cancers and cardiovascular diseases,’ Thomas said.”
To read the full story: Graphene pioneer eyes biosensor market
